Subclinical Atrial Fibrillation and the Risk of Stroke

Jeff S. Healey, M.D., Stuart J. Connolly, M.D., Michael R. Gold, M.D., Carsten W. Israel, M.D., Isabelle C. Van Gelder, M.D., Alessandro Capucci, M.D., C.P. Lau, M.D., Eric Fain, M.D., Sean Yang, M.Sc., Christophe Bailleul, M.D., Carlos A. Morillo, M.D., Mark Carlson, M.D., Ellison Theemeles, M.Sc., Elizabeth S. Kaufman, M.D., and Stefan H. Hohnloser, M.D., for the ASSERT Investigators*

From the Population Health Research Institute, McMaster University, Hamilton, ON, Canada (J.S.H., S.J.C., S.Y., C.A.M., E.T.); the Medical University of South Carolina, Charleston (M.R.G.); J.W. Goethe University, Frankfurt, Germany (C.W.I., S.H.H.); University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (I.C.V.G.); Clinica di Cardiologia, Università Politecnica delle Marche, Ancona, Italy (A.C.); Queen Mary Hospital, Department of Medicine, University of Hong Kong, Hong Kong, China (C.P.L.); St. Jude Medical, Sylmar, CA, and Zaventem, Belgium (E.F., C.B., M.C.); and Metro Health Campus of Case Western Reserve University, Cleveland (E.S.K.). Address reprint requests to Dr. Connolly at the Population Health Research Institute, McMaster University, 237 Barton St. E., Hamilton, ON L8L 2X2, Canada, or at connostu@phri.ca.

*The investigators in the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT) are listed in the Supplemental Appendix, available at NEJM.org.

This article was updated on February 22, 2016, at NEJM.org.


ABSTRACT

BACKGROUND
One quarter of strokes are of unknown cause, and subclinical atrial fibrillation may be a common etiologic factor. Pacemakers can detect subclinical episodes of rapid atrial rate, which correlate with electrocardiographically documented atrial fibrillation. We evaluated whether subclinical episodes of rapid atrial rate detected by implanted devices were associated with an increased risk of ischemic stroke in patients who did not have other evidence of atrial fibrillation.

METHODS
We enrolled 2580 patients, 65 years of age or older, with hypertension and no history of atrial fibrillation, in whom a pacemaker or defibrillator had recently been implanted. We monitored the patients for 3 months to detect subclinical atrial tachyarrhythmias (episodes of atrial rate >190 beats per minute for more than 6 minutes) and followed them for a mean of 2.5 years for the primary outcome of ischemic stroke or systemic embolism. Patients with pacemakers were randomly assigned to receive or not to receive continuous atrial overdrive pacing.

RESULTS
By 3 months, subclinical atrial tachyarrhythmias detected by implanted devices had occurred in 261 patients (10.1%). Subclinical atrial tachyarrhythmias were associated with an increased risk of clinical atrial fibrillation (hazard ratio, 5.56; 95% confidence interval [CI], 3.78 to 8.17; P<0.001) and of ischemic stroke or systemic embolism (hazard ratio, 2.49; 95% CI, 1.28 to 4.85; P = 0.007). Of 51 patients who had a primary outcome event, 11 had had subclinical atrial tachyarrhythmias detected by 3 months, and none had had clinical atrial fibrillation by 3 months. The population attributable risk of stroke or systemic embolism associated with subclinical atrial tachyarrhythmias was 13%. Subclinical atrial tachyarrhythmias remained predictive of the primary outcome after adjustment for predictors of stroke (hazard ratio, 2.50; 95% CI, 1.28 to 4.89; P = 0.008). Continuous atrial overdrive pacing did not prevent atrial fibrillation.

CONCLUSIONS
Subclinical atrial tachyarrhythmias, without clinical atrial fibrillation, occurred frequently in patients with pacemakers and were associated with a significantly increased risk of ischemic stroke or systemic embolism. (Funded by St. Jude Medical; ASSERT ClinicalTrials.gov number, NCT00256152.)
Atrial Fibrillation May Be Asymptomatic and Consequently Subclinical.\textsuperscript{1-3} Epidemiologic studies indicate that many patients with atrial fibrillation on screening electrocardiograms had not previously received a diagnosis of atrial fibrillation.\textsuperscript{3} About 15\% of strokes are attributable to documented atrial fibrillation, and 50 to 60\% to documented cerebrovascular disease,\textsuperscript{4-7} but in about 25\% of patients who have ischemic strokes, no etiologic factor is identified.\textsuperscript{4,8,9} Subclinical atrial fibrillation is often suspected to be the cause of stroke in these patients.\textsuperscript{10} However, the prevalence and prognostic value of subclinical atrial fibrillation has been difficult to assess.\textsuperscript{8,9,11,12}

An implanted atrial lead that is in position over the long term, with the analytic software of the modern pacemaker, allows the continuous detection and characterization of individual episodes of rapid atrial rate over long periods.\textsuperscript{12} Studies have indicated that, depending on the programming of the pacemaker, the detection of such episodes of rapid atrial rate correlates well with electrocardiographic documentation of atrial fibrillation.\textsuperscript{12} There are more than 400,000 pacemakers and implantable cardioverter–defibrillators (ICDs) implanted each year in North America.\textsuperscript{13-15} Subclinical episodes of rapid atrial rate are detected in many of these patients,\textsuperscript{16,17} often in the absence of clinical evidence of atrial fibrillation. The rate of stroke is also high among patients who have received a pacemaker, with stroke occurring in 5.8\% of the patients within 4 years after implantation.\textsuperscript{18} However, the relationship between device-detected atrial tachyarrhythmias and stroke is not understood.

The Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT) was designed to address two objectives. The first was to prospectively evaluate whether subclinical episodes of rapid atrial rate detected by implanted devices are associated with an increased risk of ischemic stroke in patients who do not have other evidence of atrial fibrillation.\textsuperscript{19} The second was to study in a randomized trial the efficacy of continuous atrial overdrive pacing in preventing clinical atrial fibrillation.

METHODS

STUDY OVERSIGHT
The details of the design of ASSERT have been published previously.\textsuperscript{19} The steering committee (see the Supplementary Appendix, available with the full text of this article at NEJM.org) designed the study, and the data were collected and analyzed by the Population Health Research Institute (McMaster University, Hamilton, ON, Canada). The sponsor (St. Jude Medical) had nonvoting membership on the steering committee and assisted in the design of the study and in on-site data collection but had no role in the analysis of the data, the preparation of the manuscript, or the decision to submit the manuscript for publication. The first two authors vouch for the completeness and accuracy of the data and the analyses and for the fidelity of the report to the study protocol, which is available at NEJM.org.

PATIENT POPULATION
Patients were eligible for inclusion in the study if they were 65 years of age or older, had a history of hypertension requiring medical therapy, and had undergone their first implantation of a St. Jude Medical dual-chamber pacemaker (for sinus-node or atrioventricular-node disease) or ICD (for any indication) in the preceding 8 weeks. Patients were excluded if they had any history of atrial fibrillation or atrial flutter lasting more than 5 minutes or if they required treatment with a vitamin K antagonist for any reason.

STUDY PROCEDURES
After providing written informed consent, patients had their pacemaker or ICD programmed according to protocol-specific settings.\textsuperscript{20} The device was programmed so that atrial tachycardia was detected when the heart rate reached 190 beats per minute, electrogram storage was activated, and the atrial fibrillation suppression algorithm was turned off.

At a clinic visit 3 months later, the devices were interrogated in order to classify patients according to whether a subclinical atrial tachyarrhythmia had occurred or had not occurred since the time of enrollment. A subclinical atrial tachyarrhythmia was defined as an episode of rapid atrial rate (190 beats or more per minute), lasting more than 6 minutes, that was detected by the pacemaker or defibrillator.

Also at the 3-month visit, patients with pacemakers (but not patients with ICDs) were randomly assigned to have continuous atrial overdrive pacing programmed as either “on” or “off.” When this feature is turned on, atrial pacing is initiated, with continuous electronic adjustment...
to pace the atrium at a rate slightly higher than the patient’s intrinsic sinus rhythm, as a means of potentially preventing the initiation of atrial fibrillation. Patients were then followed every 6 months to the end of the study.

**STUDY OUTCOMES**

For the portion of the study in which the prognostic value of subclinical atrial fibrillation was evaluated, the primary outcome was ischemic stroke or systemic embolism. Secondary outcomes were vascular death, myocardial infarction, stroke from any cause, and atrial tachyarrhythmias documented by surface electrocardiography. The definitions of the individual outcome events are provided in the Supplementary Appendix. All the available device electrograms that showed subclinical atrial tachyarrhythmias, as well as all clinical events, were subject to blinded adjudication by expert committees.

The primary outcome of the randomized trial of continuous atrial overdrive pacing was symptomatic or asymptomatic atrial tachyarrhythmia lasting more than 6 minutes, documented by surface electrocardiographic recording. The results of this randomized comparison are presented only briefly in this report, since this report is intended to focus primarily on the findings of the observational study of the prognostic value of subclinical atrial fibrillation.

**STATISTICAL ANALYSIS**

On the basis of previously reported data, we estimated that the annual rate of stroke or systemic embolism in patients 65 years of age or older who have hypertension and who have received a pacemaker would be approximately 1%. We then estimated that with enrollment of 2500 patients, the study would have 90% power to detect an increase in the annual risk of ischemic stroke or systemic embolism from 1% to 2% among patients who have had an episode of rapid atrial rate. For the randomized portion of the study, we also estimated that with 2500 patients enrolled, the study would have 90% power to detect a 25% reduction with continuous atrial overdrive pacing in the rate of development of clinical atrial tachyarrhythmias, from a control rate of 8% per year.

The baseline characteristics of patients with and of patients without a subclinical atrial tachyarrhythmia before the 3-month visit were compared with the use of independent t-tests or Fisher’s exact test. The primary outcome analysis was a comparison between these two groups of the cumulative risk of ischemic stroke or systemic embolism occurring after the 3-month visit. Cumulative hazard curves were modeled with the use of the Kaplan–Meier method and were compared with the use of a log-rank test. Cox proportional-hazards modeling was used to adjust for baseline imbalances with respect to prior or no prior stroke or transient ischemic attacks, presence or absence of diabetes mellitus, presence or absence of heart failure, age, sex, and history or no history of coronary artery disease or peripheral arterial disease.

A prespecified analysis was performed according to the baseline CHADS₂ score of the patients. Scores on the CHADS₂, an index of the risk of stroke in patients with atrial fibrillation, range from 0 to 6, with higher scores indicating a greater risk of stroke. An analysis was also performed in which data from patients were censored once clinical atrial fibrillation developed. A time-dependent covariate analysis was performed with the use of data on all atrial tachyarrhythmias that occurred during the study; in this analysis, the detection of a subclinical atrial tachyarrhythmia (of >6 minutes’ duration, >6 hours’ duration, or >24 hours’ duration) triggered a time-dependent variable that remained positive for the remainder of the follow-up period. Data from the randomized evaluation of continuous atrial overdrive pacing were analyzed according to the intention-to-treat principle, with the use of Cox proportional-hazards modeling and log-rank testing.

**RESULTS**

**STUDY PATIENTS**

During the period from December 2004 through September 2009, a total of 2451 patients with a newly implanted pacemaker and 129 patients with a newly implanted ICD were enrolled in 23 countries. Between the time of enrollment and the 3-month visit, at least one atrial tachyarrhythmia was detected by an implanted device in 261 patients (10.1%). During this same period, clinical atrial tachyarrhythmias occurred in 7 patients.

Among patients who had subclinical atrial tachyarrhythmias within 3 months after implantation of a device, the median number of episodes of atrial arrhythmia was 2 (interquartile range, 1 to 3). The median atrial rate was 480 beats per minute (interquartile range, 366 to 549), and the median time to detection of the first episode was 35 days (interquartile range, 11 to 66).
The age of the patients and the percentage of patients who had a prior stroke were similar in the group with subclinical atrial tachyarrhythmias before the 3-month visit and in the group without a subclinical tachyarrhythmia before that visit (Table 1). The prevalence of sinus nodal disease was higher, and the resting heart rate was lower, among patients with subclinical atrial tachyarrhythmias than among those without a subclinical tachyarrhythmia. Aspirin was used by 61.3% and 61.7% of the patients in the two groups, respectively, and none of the patients were receiving a vitamin K antagonist at baseline.

**Atrial Tachyarrhythmias during the Follow-up Period**

Patients were subsequently followed for a mean of 2.5 years, during which time 14 patients (0.5%) were lost to follow-up. Over the course of the follow-up period, 194 patients received a vitamin K antagonist, including 47 of the patients who had had a subclinical atrial tachyarrhythmia by 3 months (18.0%).

During the follow-up period, subclinical atrial tachyarrhythmias occurred in an additional 633 patients (24.5%). Clinical atrial tachyarrhythmias on surface electrocardiograms occurred in 41 of the 261 patients who had had subclinical atrial tachyarrhythmias before the 3-month visit (15.7%) and in 71 of the 2319 patients who had not had subclinical atrial tachyarrhythmias before the 3-month visit (3.1%) (hazard ratio, 5.56; 95% confidence interval [CI], 3.78 to 8.17; P<0.001) (Table 2 and Fig. 1A).

**Stroke or Systemic Embolism**

During the follow-up period, 11 of the 261 patients (4.2%) in whom subclinical atrial tachyarrhythmias had been detected before 3 months had an ischemic stroke or systemic embolism (a rate of 1.69% per year), as compared with 40 of the 2319 patients who had had subclinical atrial tachyarrhythmias before the 3-month visit (1.7%) (hazard ratio, 5.56; 95% confidence interval [CI], 3.78 to 8.17; P<0.001) (Table 2 and Fig. 1B). The risk was virtually unchanged after adjustment for baseline risk factors for stroke (hazard ratio, 2.49; 95% CI, 1.28 to 4.85; P=0.007) (Table 2 and Fig. 1B). The risk was virtually unchanged after adjustment for baseline risk factors for stroke (hazard ratio, 2.49; 95% CI, 1.28 to 4.85; P=0.007) (Table 2 and Fig. 1B).

In the time-dependent analysis that included all episodes of atrial tachyarrhythmia detected by devices during the follow-up period, episodes lasting longer than 6 minutes, as compared with no episodes, were associated with an increased risk of ischemic stroke or systemic embolism (hazard ratio, 2.99; 95% CI, 1.55 to 5.77; P=0.001) and when the occurrence of episodes longer than 6 hours was compared with the occurrence of no episodes (hazard ratio, 4.96; 95% CI, 2.39 to 10.3; P<0.001). When the patients with episodes of device-detected atrial tachyarrhythmia were stratified according to the duration, in quartiles, of the longest episode (≤0.86 hours, 0.87 to 3.63 hours, 3.64 to 17.72 hours, and >17.72 hours), the annual rates of stroke or systemic embolism were 1.23 (95% CI, 0.15 to 4.46), 0 (95% CI, 0 to 2.08), 1.18 (95% CI, 0.14 to 4.28), and 4.89 (95% CI, 1.96 to 10.07), respectively. A similar analysis of the number of episodes of subclinical atrial tachyarrhythmia, in quartiles (1, 2, 3 or 4, and >4) yielded annual rates of stroke or systemic embolism of 1.20 (95% CI, 0.25 to 3.50), 2.15 (95% CI, 0.44 to 6.29), 1.89 (95% CI, 0.23 to 6.81), and 1.93 (95% CI, 0.40 to 5.63), respectively.

The relative risk of ischemic stroke or systemic embolism associated with subclinical atrial tachyarrhythmia was consistent across increasing levels of baseline risk of stroke, as assessed by the CHADS2 score (Table 3). The absolute rate of stroke increased with increasing CHADS2 score, reaching a rate of 3.78% per year in patients with subclinical atrial tachyarrhythmias and a CHADS2 score of greater than 2.

**Randomized Evaluation of Continuous Atrial Overdrive Pacing**

We also randomly assigned all patients with pacemakers to receive continuous atrial overdrive pacing or not to receive it; the baseline characteristics of these two groups were well balanced (Table 1). The rate of the development of a clinical atrial fibrillation by 3 months, and none had had clinical atrial fibrillation by 3 months. The population attributable risk of ischemic stroke or systemic embolism associated with subclinical atrial tachyarrhythmia was 13%. There was no association between subclinical atrial tachyarrhythmias and any of the other clinical outcomes (Table 2).
The intervention did not have a significant effect on any other outcome (Table 4). In an analysis of the prognostic value of subclinical atrial tachyarrhythmias with patients stratified according to randomized study group (continuous atrial overdrive pacing vs. no continuous atrial overdrive pacing), a test of interaction was not significant (P = 0.995).

Table 1. Baseline Characteristics of the Patients.*

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Device-Detected Subclinical Atrial Tachyarrhythmia</th>
<th>Continuous Atrial Overdrive Pacing†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes (N = 261)</td>
<td>Off (N = 1179)</td>
</tr>
<tr>
<td>Age — yr</td>
<td>77±7</td>
<td>76±7</td>
</tr>
<tr>
<td>Male sex — no. (%)</td>
<td>147 (56.3)</td>
<td>687 (59.0)</td>
</tr>
<tr>
<td>Systolic blood pressure while sitting — mm Hg</td>
<td>137±20</td>
<td>139±20</td>
</tr>
<tr>
<td>Heart rate — beats/min</td>
<td>68±12</td>
<td>70±11</td>
</tr>
<tr>
<td>Body-mass index‡</td>
<td>28±5</td>
<td>27±5</td>
</tr>
<tr>
<td>Risk factors for stroke — no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prior stroke</td>
<td>18 (6.9)</td>
<td>80 (6.9)</td>
</tr>
<tr>
<td>Prior transient ischemic attack</td>
<td>13 (5.0)</td>
<td>52 (4.5)</td>
</tr>
<tr>
<td>History of heart failure</td>
<td>39 (14.9)</td>
<td>142 (12.2)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>59 (22.6)</td>
<td>329 (28.3)</td>
</tr>
<tr>
<td>Prior myocardial infarction</td>
<td>32 (12.3)</td>
<td>175 (15.0)</td>
</tr>
<tr>
<td>CHADS2 score§</td>
<td>2.2±1.1</td>
<td>2.2±1.0</td>
</tr>
<tr>
<td>Sinus-node disease, with or without atrioventricular-node disease — no. (%)</td>
<td>130 (49.8)</td>
<td>519 (44.6)</td>
</tr>
<tr>
<td>Atrioventricular-node disease — no. (%)</td>
<td>132 (50.6)</td>
<td>648 (55.7)</td>
</tr>
<tr>
<td>Atrial lead in septal position — no. (%)</td>
<td>101 (38.7)</td>
<td>492 (42.3)</td>
</tr>
<tr>
<td>Duration of hypertension &gt;10 yr — no. (%)</td>
<td>115 (44.1)</td>
<td>486 (41.8)</td>
</tr>
<tr>
<td>Left ventricular hypertrophy on ECG — no. (%)</td>
<td>6 (2.3)</td>
<td>46 (4.0)</td>
</tr>
<tr>
<td>Time from implantation of pacemaker or ICD to enrollment — days</td>
<td>25±22</td>
<td>28±39</td>
</tr>
<tr>
<td>Medications — no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>160 (61.3)</td>
<td>721 (61.9)</td>
</tr>
<tr>
<td>Beta-blocker</td>
<td>94 (36.0)</td>
<td>398 (34.2)</td>
</tr>
<tr>
<td>Statin</td>
<td>113 (43.3)</td>
<td>544 (46.7)</td>
</tr>
</tbody>
</table>

* Plus–minus values are means ±SD. The baseline characteristics of the patients are shown according to whether subclinical atrial tachyarrhythmias were or were not detected between enrollment and 3 months and according to whether patients were randomly assigned after the 3-month visit to have continuous atrial overdrive pacing turned on or off. All patients had a history of hypertension requiring treatment, and no patients were receiving vitamin K antagonist therapy. ECG denotes electrocardiogram, and ICD implantable cardioverter–defibrillator.
† Only patients receiving a pacemaker were enrolled in the portion of the trial in which patients were randomly assigned after the 3-month visit to have continuous atrial overdrive pacing turned on or turned off. There were no significant differences between the two randomized treatment groups in any of the baseline characteristics shown (P>0.05 for all comparisons).
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§ The CHADS2 score is used to predict the risk of stroke in patients with atrial fibrillation. Scores range from 0 to 6, with higher scores indicating a greater risk of stroke: the categories of congestive heart failure, hypertension, diabetes, and an age of 75 years or older are each assigned 1 point, and the category of prior stroke or transient ischemic attack is assigned 2 points.
A table showing the adverse events that occurred during the randomized portion of the trial is provided in the Supplementary Appendix.

**DISCUSSION**

A major finding of this study is that among patients 65 years of age or older with a history of hypertension who had undergone implantation of a pacemaker or ICD and were free from clinical atrial fibrillation, there was a substantial incidence of subclinical atrial tachyarrhythmias. Subclinical atrial tachyarrhythmias were detected in one tenth of the patients within 3 months after implantation and were detected at least once during a mean follow-up period of 2.5 years in 34.7% of the patients. Episodes of subclinical atrial tachyarrhythmias were almost eight times as common as episodes of clinical atrial fibrillation. During the course of the study, clinical atrial fibrillation developed in only 15.7% of the patients with subclinical atrial tachyarrhythmias, suggesting that there can be a lag between subclinical events and clinical detection. The median time to the detection, by means of continuous device monitoring, of the occurrence of subclinical atrial tachyarrhythmias within the first 3 months was 36 days, indicating that Holter monitoring even for several days may fail to detect subclinical atrial fibrillation.

The second major finding of the study is that subclinical atrial tachyarrhythmias were independently associated with an increase by a factor of 2.5 in the risk of ischemic stroke or systemic embolism and that this risk was independent of other risk factors for stroke and of the presence of clinical atrial fibrillation. The population attributable risk of ischemic stroke or systemic embolism associated with subclinical atrial tachyarrhythmias before 3 months was 13%, which is similar to the attributable risk of stroke associated with clinical atrial fibrillation reported by the Framingham investigators. The results of our study suggested that the risk of stroke was higher when episodes of subclinical atrial tachyarrhythmias were longer duration, but the study was underpowered for this analysis. Our study also did not analyze device-detected events of 6 minutes or less, which occurred frequently and which might be clinically important.

The risk of stroke with a device-detected atrial tachyarrhythmia was modulated by the patient’s risk profile for stroke. When a patient had a CHADS2 score of higher than 2, the risk of is-
A Risk of Clinical Atrial Tachyarrhythmias

B Risk of Ischemic Stroke or Systemic Embolism

No. at Risk
Subclinical atrial tachyarrhythmias present 261  236  222  205  160  110
Subclinical atrial tachyarrhythmias absent 2319 2146 2064 1911 1544 1176

Figure 1. The Risk of Clinical Atrial Tachyarrhythmias and of Ischemic Stroke or Systemic Embolism, According to the Presence or Absence of Subclinical Atrial Tachyarrhythmias.

Panel A shows the risk of electrocardiographically documented clinical atrial tachyarrhythmias after the 3-month visit, according to whether subclinical atrial tachyarrhythmias were or were not detected between enrollment and the 3-month visit. Panel B shows the risk of ischemic stroke or systemic embolism after the 3-month visit, according to whether subclinical atrial tachyarrhythmias were or were not detected between enrollment and the 3-month visit. The insets show the same data on an enlarged y axis.

Chronic stroke or systemic embolism associated with a subclinical atrial tachyarrhythmia was nearly 4% per year. More than half of the patients were receiving aspirin at baseline, and 18% of patients with subclinical atrial tachyarrhythmias received a vitamin K antagonist during the follow-up period. Both of these treatments could have reduced the risk of stroke and might have...
lessened the observed increase in the risk of stroke associated with subclinical atrial tachyarhythmias. The net benefit of antithrombotic treatment is well established in patients with clinical atrial fibrillation, but there may not be a similar benefit in patients with subclinical atrial tachyarrhythmias; therefore, a randomized trial of anticoagulant therapy in patients with subclinical atrial tachyarrhythmias is desirable.

Two previous studies have reported an increased risk of clinical events with device-detected atrial tachyarrhythmias, but neither study excluded patients with previously diagnosed atrial fibrillation, nor did they adjudicate episodes of device-detected atrial tachyarrhythmias. A retrospective analysis of a subgroup of 312 patients from the Mode Selection Trial (MOST; ClinicalTrials.gov number, NCT00000561)\(^1\) showed that the risk of death or stroke was increased by a factor of 2.5 in patients who had at least one episode of high atrial rate. Glotzer et al. also reported a relationship between device-detected atrial tachycardia and embolic events.\(^2\) However, that study also included patients with previously documented atrial fibrillation and did not show a significant association in the predefined primary analysis.

The prevalence of subclinical atrial tachyarhythmias may be higher in patients with pacemakers than in other high-risk patient groups. Sinus-node dysfunction is associated with an increased risk of atrial fibrillation.\(^3,4\) Furthermore, patients with atrioventricular-node disease may be more likely to be asymptomatic when atrial tachyarrhythmias occur, owing to reduced atrioventricular conduction. Nonetheless, the prevalence of subclinical atrial fibrillation in other elderly populations may be high.\(^5\) In the Cardiovascular Health Study involving randomly selected persons 65 years of age or older,\(^6\) atrial fibrillation was diagnosed by electrocardiography in 2% of the patients; 14% of those patients had no previous diagnosis of atrial fibrillation.

A link between stroke of unknown cause, often called cryptogenic stroke, and subclinical atrial fibrillation has long been suspected. Short-term monitoring studies have shown that subclinical atrial fibrillation is present in some patients who have had a cryptogenic stroke,\(^7,8\) but long-term continuous monitoring, like that available with a pacemaker, is currently not practical. The data from the present study support the concept that there is a link between subclinical atrial fibrillation and cryptogenic stroke.

The results of this study did not show a benefit of continuous atrial overdrive pacing. However, because the rate of development of clinical atrial fibrillation was low, the study was underpowered for this outcome. Algorithms for continuous atrial overdrive pacing have been evaluated in previous trials,\(^9-14\) but most of the trials have had small sample sizes, and there have been differences among the trials in the characteristics of the patient populations, the pacing algorithms used, and the atrial lead positions. These trials have not provided convincing evidence of a benefit.\(^9-14\)

The present data provide modest evidence that this intervention does not prevent clinical atrial fibrillation.

---

Table 3. Risk of Ischemic Stroke or Systemic Embolism after the 3-Month Visit, According to Baseline CHADS\(_2\) Score and According to Whether Subclinical Atrial Tachyarrhythmias Were or Were Not Detected between Enrollment and the 3-Month Visit.

<table>
<thead>
<tr>
<th>CHADS(_2) Score</th>
<th>No. of Patients</th>
<th>Subclinical Atrial Tachyarrhythmias between Enrollment and 3 Months</th>
<th>Hazard Ratio for Ischemic Stroke or Systemic Embolism with Subclinical Atrial Tachyarrhythmias (95% CI)(^*)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>no. of patients</td>
<td>no. of events</td>
<td>%/yr</td>
</tr>
<tr>
<td>1</td>
<td>600</td>
<td>68</td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td>1129</td>
<td>119</td>
<td>4</td>
</tr>
<tr>
<td>&gt;2</td>
<td>848</td>
<td>72</td>
<td>6</td>
</tr>
</tbody>
</table>

* The P value for trend is 0.35.
Table 4. Effect of Continuous Atrial Overdrive Pacing on Clinical Outcomes.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Continuous Atrial Overdrive Pacing Turned On (N = 1164)</th>
<th>Continuous Atrial Overdrive Pacing Turned Off (N = 1179)</th>
<th>Hazard Ratio with Continuous Atrial Overdrive Pacing Turned On (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of Patients</td>
<td>Annual Ratea</td>
<td>No. of Patients</td>
<td>Annual Ratea</td>
</tr>
<tr>
<td>Atrial tachyarrhythmia†</td>
<td>60</td>
<td>1.96</td>
<td>45</td>
<td>1.44</td>
</tr>
<tr>
<td>Symptomatic</td>
<td>29</td>
<td>0.95</td>
<td>22</td>
<td>0.71</td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>36</td>
<td>1.17</td>
<td>28</td>
<td>0.90</td>
</tr>
<tr>
<td>Device-detected atrial tachyarrhythmia with duration &gt; 24 hr</td>
<td>134</td>
<td>4.37</td>
<td>125</td>
<td>4.01</td>
</tr>
<tr>
<td>Stroke, systemic embolism, myocardial infarction, death from vascular causes, or hospitalization for heart failure</td>
<td>160</td>
<td>5.22</td>
<td>146</td>
<td>4.69</td>
</tr>
<tr>
<td>Stroke</td>
<td>21</td>
<td>0.68</td>
<td>25</td>
<td>0.80</td>
</tr>
<tr>
<td>Systemic embolism</td>
<td>3</td>
<td>0.10</td>
<td>2</td>
<td>0.06</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>22</td>
<td>0.72</td>
<td>20</td>
<td>0.64</td>
</tr>
<tr>
<td>Death from vascular causes</td>
<td>82</td>
<td>2.67</td>
<td>80</td>
<td>2.57</td>
</tr>
<tr>
<td>Hospitalization for heart failure</td>
<td>77</td>
<td>2.51</td>
<td>59</td>
<td>1.89</td>
</tr>
</tbody>
</table>

a The annual rate is the rate per 100 patient-years of follow up.
† Symptomatic or asymptomatic atrial tachyarythmia (atrial rate of >190 beats per minute) lasting more than 6 minutes, documented by surface electrocardiographic recording, was the primary outcome of the randomized trial of continuous atrial overdrive pacing.

In summary, subclinical atrial tachyarrhythmias occurred frequently in patients with pacemakers who had a history of hypertension but no prior diagnosis of clinical atrial fibrillation. The subclinical atrial tachyarrhythmias often preceded the development of clinical atrial fibrillation. In patients with pacemakers who did not have clinical atrial fibrillation, the occurrence of subclinical atrial tachyarrhythmias was associated with a significantly increased risk of a subsequent stroke.

Supported by St. Jude Medical.

Dr. Healey reports receiving consulting fees from St. Jude Medical, Boehringer Ingelheim, and Bayer and grant support from Boehringer Ingelheim, Boston Scientific, and AstraZeneca; Dr. Connolly, receiving grant support and lecture fees from St. Jude Medical; Dr. Gold, receiving fees for board membership from St. Jude Medical and Medtronic, consulting fees from St. Jude Medical and Medtronic, grant support from St. Jude Medical, Boston Scientific, Sorin, and Medtronic, and lecture fees from St. Jude Medical, Boston Scientific, Medtronic, and Biotronik; Dr. Israel, receiving fees for board membership from Medtronic and lecture fees and reimbursement for travel expenses from Boston Scientific, Medtronic, Sorin, St. Jude Medical, and Biotronik; Dr. Van Gelder, receiving consulting fees from Boehringer Ingelheim, Medtronic, and Sanofi-Aventis, grant support from Medtronic and Biotronik, and lecture fees from Boehringer Ingelheim, Medtronic, Merck, and Sanofi-Aventis; Dr. Capucci, receiving consulting fees from Merck, Sanofi-Aventis, and Meda Pharmaceuticals, lecture fees from Merck and Sanofi-Aventis, and reimbursement for meeting expenses from Sorin, Boston Scientific, Merck, and Sanofi-Aventis; Dr. Fain, being employed by and receiving stock, fees for patents, and reimbursement for meeting expenses from St. Jude Medical; Dr. Bailleul, being employed by and receiving stock from St. Jude Medical; Dr. Morillo, receiving consulting fees from St. Jude Medical, Biotronik, Medtronic, Boston Scientific, Sanofi-Aventis, and Boehringer Ingelheim, grant support from St. Jude Medical, Medtronic, and Boston Scientific, and lecture fees from Boston Scientific, St. Jude Medical, Medtronic, Boehringer Ingelheim, Sanofi-Aventis, and Biotronik; Dr. Carlson, being employed by and receiving grant support, stock, and reimbursement for meeting expenses from St. Jude Medical; Mr. Themeles, receiving grant support from St. Jude Medical; and Dr. Hohnloser, receiving consulting fees from Sanofi-Aventis, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, and Cardiome and lecture fees from Sanofi-Aventis, St. Jude Medical, Boehringer Ingelheim, Bristol-Myers Squibb, and Pfizer. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

REFERENCES

3. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. The New England Journal of Medicine

Downloaded from nejm.org on October 26, 2017. For personal use only. No other uses without permission. Copyright © 2012 Massachusetts Medical Society. All rights reserved.
Copyright © 2012 Massachusetts Medical Society.